This is the strongest insider signal at KRMD in recent history — the CEO personally deployed $1.4M and every other senior officer added at the open market simultaneously. Monitor for near-term company announcements (earnings, product updates, partnership). A 10b5-1 plan is unlikely given the cluster nature and non-identical timing. This cluster supports a constructive bias over the next 3-6 months.
Price Chart
Executive Summary
KORU Medical Systems insiders executed a concentrated buying cluster, with CEO Linda Tharby making a $1.42M open-market purchase at ~$3.92, while the CFO, COO, and CTO each added $19-20K at similar prices. Total cluster value of ~$1.48M represents roughly 0.81% of the $182M market cap — significant for this size company — and is amplified by the top-down C-suite participation, consistent with the academic literature showing that clustered C-suite buys are strongly predictive of positive abnormal returns.
Key Financial Metrics
Key Facts
- CEO Linda Tharby purchased 1,191 shares at ~$3.92 on 5/15, value ~$1.42M (the bulk of the cluster)
- CFO Thomas Adams bought 5,041 shares at $3.86 on 5/14 ($19.5K); also exercised 8,193 derivative shares at $0 (non-cash) and had 2,900 shares withheld for taxes
- COO Christopher Pazdan bought 5,000 shares at $3.88 on 5/14 ($19.4K); simultaneously exercised 5,327 derivative shares at $0 (non-cash) and surrendered 1,470 for tax withholding
- CTO Eric Schiller bought 5,000 shares at $3.9125 on 5/18 ($19.6K)
- Four unique insiders participated; three are C-suite (CEO, CFO, COO); the CTO is also a named officer
- Total open-market purchase value ~$1.48M, or ~0.81% of the $182M market cap — solidly in the 'significant' proportionality band
- Insider cluster is accompanied by cross-filing amplifiers (earnings + insider trades, offering + insider trades) per the actuarial verdicts, which support an elevated score
Financial Impact
Total insider open-market purchases of $1.48M (0.81% of market cap); CEO alone contributed $1.42M.
Risk Factors
- CEO's single large trade ($1.42M) dominates the cluster — if it was a one-time capital allocation unrelated to business outlook, the signal is weaker
- Open-market buys are not a guarantee of near-term performance; the biotech/medical device space has binary event risk
- The CFO and COO exercised derivatives at zero cost and surrendered shares for taxes — these are non-cash events and do not add conviction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KRMD-1779309717437 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 9, 2026 15w ago | Institutional Cluster | $4.43 $4.24 | ▼ −4.29% | ▼ −4.16% | $3.12 (−29.57%) |
Jun 30, 2026 16w ago | 8-K | $4.40 $4.59 | ▲ +4.32% | ▲ +4.06% | $3.12 (−29.09%) |
May 20, 2026 22w ago | Insider Cluster | $4.14 $4.18 | ▲ +0.97% | ▼ −0.63% | $3.12 (−24.64%) |
May 20, 2026 22w ago | Insider Cluster | $4.14 $4.06 | ▼ −1.93% | ▼ −3.78% | $3.12 (−24.64%) |
May 20, 2026 22w ago | Insider Cluster | $4.14 $4.18 | ▲ +0.97% | ▼ −0.63% | $3.12 (−24.64%) |
May 18, 2026 23w ago | Insider Cluster | $3.96 $4.15 | ▲ +4.80% | ▲ +2.50% | $3.12 (−21.21%) |
May 6, 2026 24w ago | 8-K | $4.44 $3.85 | ▼ −13.29% | ▼ −14.79% | $3.12 (−29.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers